上海医药(02607.HK)旗下治疗关节炎原料药获内地批准生产

阿斯达克财经07-08

上海医药(02607.HK) (601607.SH) 公布，其全资子公司上药中西的枸橼酸托法替布原料药近日收到国家药监局颁发的《化学原料药上市申请批准通知书》，该药品获得批准生产。

枸橼酸托法替布主要适用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎，由辉瑞(PFE.US) 研发，制剂最早于2012年美国上市。截至目前，公司针对该药物已投入研发费用约1,269万元人民币。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-08 16:25。) (A股报价延迟最少十五分钟。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)

AASTOCKS新闻

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2449763729?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210429113036647_s.jpg","is_english":false,"pubTime":"2024-07-08 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2449763729","market":"fut","top_or_hot":-1,"title":"上海医药(02607.HK)旗下治疗关节炎原料药获内地批准生产","media":"阿斯达克财经","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/601607\">上海医药</a>(02607.HK)<span> </span>(601607.SH)<span> </span>公布，其全资子公司上药中西的枸橼酸托法替布原料药近日收到国家药监局颁发的《化学原料药上市申请批准通知书》，该药品获得批准生产。<br/><span></span><br/>枸橼酸托法替布主要适用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE.US)<span> </span><span> </span>研发，制剂最早于2012年美国上市。截至目前，公司针对该药物已投入研发费用约1,269万元人民币。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-08 16:25。) (A股报价延迟最少十五分钟。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>上海医药(02607.HK)旗下治疗关节炎原料药获内地批准生产</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n上海医药(02607.HK)旗下治疗关节炎原料药获内地批准生产\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯达克财经</strong><span class=\"h-time small\">2024-07-08 17:04</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div> <span> <p><a href=\"https://laohu8.com/S/601607\">上海医药</a>(02607.HK)<span> </span>(601607.SH)<span> </span>公布，其全资子公司上药中西的枸橼酸托法替布原料药近日收到国家药监局颁发的《化学原料药上市申请批准通知书》，该药品获得批准生产。<br/><span></span><br/>枸橼酸托法替布主要适用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE.US)<span> </span><span> </span>研发，制剂最早于2012年美国上市。截至目前，公司针对该药物已投入研发费用约1,269万元人民币。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-08 16:25。) (A股报价延迟最少十五分钟。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1362049/latest-news/AAFN\">阿斯达克财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0020","symbol_name":"浦东新区","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1362049/latest-news/AAFN","article_id":"2449763729","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210429113036647_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2449763729","pubTimestamp":1720429440,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"上海医药(02607.HK) (601607.SH) 公布，其全资子公司上药中西的枸橼酸托法替布原料药近日收到国家药监局颁发的《化学原料药上市申请批准通知书》，该药品获得批准生产。枸橼酸托法替布主要适用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎，由辉瑞(PFE.US)  研发，制剂最早于2012年美国上市。截至目前，公司针对该药物已投入研发费用约1,269万元人民币。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-08 16:25。) (A股报价延迟最少十五分钟。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"601607":"上海医药","BK0020":"浦东新区","BK0097":"医药电商","BK0099":"上海本地重组","BK0175":"白马股","BK0028":"国家队","02607":"上海医药","BK0188":"融资融券","BK0184":"上海国资改革","BK1197":"保健护理产品经销商","BK0187":"一线龙头","BK0183":"MSCI概念","BK0209":"零售","BK0012":"证金概念","BK0196":"行业龙头"},"translate_title":"Shanghai Pharmaceuticals (02607. HK) 's arthritis treatment API was approved for production in the Mainland","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"上海医药(02607.HK) (601607.SH) 公布，其全资子公司上药中西的枸橼酸托法替布原料药近日收到国家药监局颁发的《化学原料药上市申请批准通知书》，该药品获得批准生产。枸橼酸托法替布主要适用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎，由辉瑞(PFE.US)  研发，制剂最早于2012年美国上市。截至目前，公司针对该药物已投入研发费用约1,269万元人民币。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-08 16:25。) (A股报价延迟最少十五分钟。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.0","shortVersion":"4.25.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2449763729"}